Key facts
- Imbed Biosciences’s last known valuation is $15.7M (Oct 2019).
- It has raised $40.0M across 8 recorded rounds; the latest was Seed Round ($3.5M) in Dec 2023.
- Notable investors include US National Science Foundation, National Institutes of Health, Pegasus Tech Ventures, WARF Ventures, Francis Family Fund — 15 tracked in total.
- Imbed Biosciences has filed 10 Form Ds with the SEC since 2014, most recently Dec 2023 ($3.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Imbed Biosciences
Funding rounds
8 roundsAbout Imbed Biosciences
Developer of an advanced wound care device designed to protect wounds and support the healing process across acute and chronic conditions. The company offers ultra-thin, fully synthetic, bioresorbable wound matrices that combine multiple active wound care components, including broad-spectrum antimicrobial agents and targeted pain relief compounds, within a flexible and conformable polymer structure, enabling healthcare providers and care settings to manage bioburden, reduce discomfort, and support effective healing across surgical, traumatic, burn, and chronic wounds.
- Sector
- Healthcare
- HQ
- Middleton, WI, United States
- Founded
- 2010
- Employees
- 30
- Website
- imbedbio.com/
- Ownership
- Privately Held (backing)
Imbed Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imbed Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imbed Biosciences in its N-PORT filings yet. We sweep new filings monthly.